

CANCER52 THIRD ANNUAL BRIEFING

Dear All

Good to see so many key people within the less common cancer community gathered for Cancer52's Third Annual Briefing at the House of Lords.

We're aiming to write a fuller debrief but in the short term, here's a summary of the event.



Allyson Kaye, Chair Cancer52



Allyson thanked existing supporters of Cancer52 and congratulated the organisation on having built its presence and voice under the leadership of her predecessor as Chair, Simon Davies.

For the future she sees Cancer52 as a pioneering organisation able to bring all parts of the less common cancer community to the table to identify priority challenges and opportunities.

She finished by reiterating the need for support and investment in the organisation to enable infrastructure build and policy evolution.

Lord Saatchi

With a week to go till the Saatchi Bill once again reaches the House of Commons on 18th October, Lord Saatchi made an impassioned and well supported speech at our event.

As Cancer52 we welcome both the introduction of the Bill and the wider impact that Lord Saatchi's involvement in the debate has had in drawing attention to our less common cancer community.

We give below links through to the Saatchi Bill website which give some very clear guidance on how charities and individual patients can voice their support.



<http://saatchibill.tumblr.com/>

<https://www.facebook.com/SaatchiBill>

National Clinical Director for Cancer, Sean Duffy



Explained how his role differs from that of his predecessor, Prof Sir Mike Richards, not least in that he (Sean) is a clinician.

He believes that with the new challenges within the new NHS come new opportunities and listed amongst his priorities early diagnosis, screening, reduction in emergency presentations, survivorship and preventing ageism.

Baroness Delyth Morgan of Drefelin

Remains, for which we are all extremely grateful, our Honorary President. She chaired and hosted our meeting including a very lively question and answer session from within the gathered stakeholders.



Topics discussed included GP symptom knowledge, ageism, need for innovation within surgery as well as drug treatment, potential impact of Saatchi Bill outside the UK, and finally many votes of support for Lord Saatchi.

Comments included a welcome for the Bill and an endorsement of Lord Saatchi's brave actions as an individual at a time of considerable challenge for him.

Finally our thanks once again to all who attended and made it such a vibrant and positive meeting. It emphasises that the voice of Cancer52 and less common cancers is increasingly heard.

Jane Lyons
Chief Executive, Cancer52



Bristol-Myers Squibb Company



Supporting the work of Cancer52

For further information contact info@cancer52.org.uk

www.cancer52.org.uk

Cancer52 is a not for profit company limited by guarantee
registered in England and Wales with company number 7994413



This email was sent to ingrid@thecybersec.co.uk by info@cancer52.org.uk |
[Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

Cancer52 | PO Box 7757 | London | W1A 3FN | England